26th Annual Biotech in Europe Forum

Anaveon AG is a late-stage preclinical biotechnology company headquartered in Basel, Switzerland. The company is dedicated to transforming lives by precisely modulating the immune system to address high unmet needs in autoimmune diseases and inflammatory disorders. Our therapeutics target central regulatory nodes of the immune system to selectively eliminate or reprogram pathogenic immune cells and restore durable immune balance. Anaveon is backed by Syncona, Forbion, Blue Owl, Novartis Venture Fund, Pfizer Ventures and Pontifax.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.

Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.

Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.

Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.

HGF supports clients across Europe and internationally in IP strategy, patents, trade marks, designs, portfolio management, due diligence, oppositions and appeals, litigation, transactional IP and commercial matters.

Micreos is a pharmaceutical biotech based in Zug, Switzerland that discovers & develops recombinant engineered endolysin proteins that act on disease pathways in Dermatology, Oncology and Infectious disease conditions.

Our business model is focused on drug discovery & early drug development (up until clinical proof of concept) with subsequent M&A at an asset level for Phase-III development and global commercialization.
The experienced leadership team consists of a complementary blend of seasoned leaders from both big-pharma and smaller-biotech. The team has the experience and ‘knows-what-it-takes’ to bring molecules all the way through successful discovery, development, registration, reimbursement & commercialization.

Nucleus Network is a global early-phase clinical research organisation with Phase 1 clinics in Australia, the UK and the US. With over 30 years’ experience and 2,500+ trials conducted, we support sponsors from study design through clinical delivery.

One04 Therapeutics is a clinical-stage biopharmaceutical company developing CPV-104, a first-in-class, full-length recombinant human Factor H therapy with disease-modifying and pipeline-in-a-molecule potential across a broad range of complement-mediated diseases. CPV-104 is designed to restore natural complement regulation and protect host tissues while preserving broader complement functions important for homeostasis and immune defense. Following favorable Phase 1 interim results in C3 glomerulopathy (C3G), CPV-104 is advancing toward Phase 2 development in complement-mediated kidney diseases and Phase 1 development in dry age-related macular degeneration (AMD) / geographic atrophy (GA).

SynAct Pharma AB is a clinical stage biotechnology company focused on developing novel resolution therapies for inflammatory diseases. Lead program, Resomelagon, phase 2 studies demonstrated clinical concept for Rheumatoid Arthritis (RA) without suppressing the immune system.

· First-in-class MoA for resolution of inflammation without immunosuppression
· Biased melanocortin receptor agonism induced cell modulation
· Phase 3 readiness initiated for competitive multi-billion-dollar RA opportunity
· Near term catalysts: Phase 3 study feedback from FDA and EMA; Strategic partnering; Further data from studies in RA and dengue virus.

Active development for autoimmune diseases (lead indication: rheumatoid arthritis) and host-directed therapy in viral infections (Dengue; Respiratory Viral).

AdCab is a pre-clinical, Helsinki-based biotech spinning out of Prof. Vincenzo Cerullo's IVT Lab at the University of Helsinki. It's developing a precision oncolytic adenovirus armed with a proprietary Fc Dual Engager — an engineered IgG/IgA chimeric Fc-PD-L1 fusion peptide — designed for immunosuppressive, hard-to-treat cancers (pancreatic ductal adenocarcinoma, triple-negative breast cancer, and microsatellite-stable colorectal cancer) that don't respond to any approved immunotherapy.

How it works: Injected directly into the tumor, the virus spares healthy tissue and converts tumor cells into biofactories that locally produce the Fc Dual Engager. This achieves two things at once — clearing the tumor's immunosuppressive cell barrier (MDSCs, TAMs) and activating a broad range of immune effector cells (NK cells, CD8+ T cells, neutrophils) — something standard checkpoint inhibitors, which only block a single axis, cannot do.

Evidence base: 80+ in-vitro tests, 15+ in-vivo studies and patient-derived organoids, and 5 manuscripts published in journals including JITC, Molecular Therapy: Oncolytics, and Nature Communications. Data show superior tumor control versus PD-L1 checkpoint blockade and a durable, vaccine-like memory response with no relapse on tumor re-challenge.

Platform potential: Built on the modular GAMER-Ad method, positioning AdCab beyond a single asset as an engine for generating new compounds against additional targets.

Team: Prof. Vincenzo Cerullo (Inventor, Head of Drug Discovery, Univ. of Helsinki), Dr. Firas Hamdan (Scientific Lead & Inventor), and Dr. Tuuli Ranki (Commercialization Lead, ex-Sanofi/Gilead, co-founder of Valo Therapeutics) — a team with 150+ publications and 20+ patents between them.

Traction: IP filed in the US, EU, and Finland; recent wins include Best Presenter at BioUK BioSeed 2026 (London) and Best Pitch at the Finnish Biotech & Investor Summit (June 2026).

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2) AdoXLong™, a long-acting peptide platform; 3) AdOral®, an oral peptide delivery technology; and 4) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation.

Adocia holds more than 25 patent families. Based in Lyon, the Company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

Rheumatoid arthritis patients are receiving methotrexate as First-Line treatment for decades. However, only 40% of patients respond to it.

Amplio Pharma is developing NovoBioJect, a product patent protected combination of methotrexate and low dose novobiocin (as ABCG2 pump inhibitor), designed to increase intracellular activity of methotrexate and to increase the number of treatment responders by 50%.

Our aim is to replace generic methotrexate with superior proprietary NovoBioJect as First-Line treatment for rheumatoid arthritis.

Recent Phase Ib results with NovoBioJect in RA patients provide biomarker based evidence of efficacy, supporting improved efficacy compared to methotrexate.

Amplio Pharma are now raising a €10m A round to fund a Phase IIa Proof-of-Concept study in RA patients.

Amporin is developing the first class of oral drugs that could stop and reverse over 50 deadly degenerative diseases, uniquely by repairing the holes in cell membranes formed by toxic misfolded protein oligomers, allowing diseased cells to fully recover and restore homeostasis. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson's disease.

Anima Biotech built BioGPU, the runtime for AI in biology.

BioGPU enables AI agents to reason inside biology through massive parallel visual biology experiments.

At the core of BioGPU is the BioGPU Runtime, which executes visual biology experiments at scale inside cells and generates thousands of Visual Biology Tokens that capture pathway activity, cellular states, regulatory mechanisms, and biological processes.

The BioGPU Agent connects to the BioGPU Runtime and uses these Visual Biology Tokens to investigate biological questions and progressively increase the resolution of disease biology.

This creates a new way for AI to interact with biology: not by reasoning only from existing knowledge, but by learning directly from biology inside cells.

As Biology Resolution Loops iterate, disease networks become increasingly resolved, enabling a deeper understanding of how pathways drive disease, what targets do, how they are regulated, and how compounds alter biology.

BioGPU enables the experimental resolution of pathways, targets, and compounds, helping scientists understand the causal biology driving disease, the function of targets, and the effects of compounds.

Our BioGPU technology has been applied across more than 20 discovery programs and strategic collaborations with AbbVie, Takeda, and Lilly.

AnimaBiotech - Biology GPU

Cancer Research and Biotechnology AG (CRB) is a Swiss late-preclinical biotechnology company developing a fundamentally different approach to cancer treatment.

Founded by pharmaceutical entrepreneur Kari Sarvanto, CRB builds on years of scientific work investigating the cellular conditions that allow cancer to develop and persist.

Its lead asset, CRB091, is an oral, fixed-dose novel therapeutic entity designed to restore upstream cellular regulatory integrity and the cell’s own ability to control malignant behavior.

CRB091 has demonstrated activity across three cancer models. In vivo, it reduced human melanoma tumor burden by 39–44%. In vitro, it reduced triple-negative breast cancer cells by 81% and colorectal cancer cells by 83% (p<0.0001), outperforming cisplatin in these experiments. A mouse TNBC study showed dose-dependent tumor reduction without the weight-loss toxicity observed with cisplatin. No toxicity has been observed in CRB studies to date.

CRB091 combines proprietary fixed-ratio biology with known constituent APIs, providing substantial existing human safety and pharmacology knowledge. CRB is pursuing a US 505(b)(2) regulatory strategy and has already engaged with the FDA as the program advances toward first-in-human development.

CRB calls the broader scientific concept Reverse Carcinogenesis: rather than only attacking the downstream consequences of cancer, asking whether restoring the disrupted cellular state itself can become a therapeutic strategy.

CB Therapeutics makes molecules chemistry can't — peptides and complex alkaloids — in engineered yeast. A pharma partner (atai, since acquired by Eli Lilly) paid us $5.5M to develop biosynthetic routes to four alkaloid classes, and we kept the IP: 14 patents granted and pending. We hold a U.S. DEA Schedule I registration (5+ years) and were first to biosynthesize psilocybin, psilocin and DMT in yeast. We are now applying the platform to our own programs: a peptide line launching H1 2027, and Korvane, a preclinical pain program in atypical-opioid alkaloids from the kratom and akuamma families. Raising $10M. Seeking investors, pharma development and licensing partners, and manufacturing partners.

Asset: CNT-201
Stage: Phase 2 ongoing (results in Q4 2026).
MoA: Recombinant Collagenase
Indications: Dupuytren's contracture (Ph 2), Peyronies Disease and Cellulite (Phase 2 in preparation)
Summary: CNT201 is a next generation therapy to Endo’s Xiaflex (US Sales of 500+ USDm). As a recombinant version free from hemolytic toxins, with potential to significantly improve both efficacy and safety. Xiaflex is not available outside the US, a further unmet need CNT201 can fill.

Pioneering the development of in vivo genetic medicines built with immune-quiet DNA.

CPTx is a leader in developing the next generation of non-viral, DNA-based in vivo CAR T cell therapies, uniquely overcoming key challenges in both oncology and autoimmune disease. CPTx’s immune-quiet proprietary DNA platform enables control over the duration of gene expression from transient to permanent, supports the co-delivery of multiple genes, and allows for repeat administration.

CureGBM is advancing a new therapeutic modality for glioblastoma: sonodynamic therapy powered by focused ultrasound. Our approach uses a sonosensitiser that readily crosses the blood–brain barrier and accumulates selectively in tumour cells. When activated by targeted ultrasound, it produces reactive oxygen species that destroy malignant tissue while sparing healthy brain. This non‑invasive, repeatable platform offers a scalable path to safer, more precise GBM treatment - and the potential to redefine outcomes in a disease that has seen little progress in decades.

Curlim is a late stage preclinical biotech company developing an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules. First applications target hereditary peripheral neuropathies and neurodegenerative diseases.

Lead indication is CMT1a, the most common hereditary neuropathy, causing lifelong progressive motor disorders beginning in childhood.

At present, there is no pharmacological treatment for nervous disorders known as peripheral neuropathies. Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy (HPN). Therapeutic strategies remain very limited and do not address the cause of the disease, but mainly its symptoms. This lack of pharmacological treatment is particularly dramatic in the case of hereditary peripheral neuropathies, as they are diffuse and often manifest very early in the patient's life and persist throughout their lifetime.

Our solution has been developed by LImoges labs (neuro and sciences) and consists of a Platform technology. The platform is a novel cationic beta-cyclodextrin crystalline-nanocrystal (B-CD/CNC) nanocarrier system for improved solubility, bioavailability, and cellular penetration of APIs.

Our compund CLM001 Targets Oxidative Stress, Heavily Implicated in Peripheral Neuropathies.

CLM001 obtained unprecedented and spectacular therapeutic effects demonstrated on 2 CMT1A animal models showing anti-inflammatory, antioxidant, and remyelinating effects, with no toxicity signals.

CLM001 shows a significant rescue in the nerve function. When treated for a total of 12 weeks, CLM001 significantly improved balance/speed and increased the nerve conductivity.

In parallel, Primary and secondary modes of action have been characterized.

From a regulatory point of view, Orphan Drug Designation has been granted both by EMA and by FDA.

CMC is finalized and next development stage will be the launch of pre-clinical toxicology study.

ErVimmune is a French biotechnology company pioneering a new class of cancer immunotherapies targeting antigens derived from human endogenous retroviruses (HERVs) - an untapped and shared source of tumor-specific epitopes.

ExpreS2ion is a clinical-stage biotechnology company turning precise protein engineering into immunotherapies for cancer and infectious diseases.

Our lead asset, ES2B-C001, is an active immunotherapy for HER2-positive and HER2-low breast cancer. Rather than delivering an antibody, it trains a patient's own immune system to produce a sustained anti-HER2 response. In our first-in-human Phase I trial, anti-HER2 antibody responses have been observed in all nine evaluable patients to date, with titres rising across dosing visits and holding at follow-up, and no safety signals of concern. The highest dose cohort opened in May 2026, with primary readout expected end-2026 and Phase II targeted for mid-2027.

ES2B-C001 is built on the ExpreS2™ platform, our proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle projects. Proteins made on the platform have been evaluated in clinical programmes worldwide, including partnered Phase III studies that met their primary endpoints.

ExpreS2ion develops VLP-based vaccines with AdaptVac ApS, in which it holds a 34% stake, and is listed on Nasdaq First North Growth Market (EXPRS2).

FINNCURE is a biotech company focusing on solutions for targeted therapies and targeted delivery of active pharmaceutical ingredients.

FluoSphera is a Swiss biotech developing scalable and transferable human-relevant 3D tissue technologies to improve drug efficacy and safety prediction while reducing reliance on animal testing.

Our proprietary platform combines Pleiad, a portfolio of ready-to-use 3D human tissues, with color-coded multi-tissue systems that recreate complex human biology in a practical, standardized format. Designed for automation and high-content analysis, the platform can be transferred and deployed across laboratories.

FluoSphera is building a portfolio of differentiated applications across efficacy, safety, DMPK-Tox and biomarker discovery. The company has established recurring pharmaceutical customers and signed its first evaluation license agreement with a global CRO, validating the transferability of the platform and its licensing potential. We are scaling through a hybrid business model combining product sales, specialized assays and technology licensing, supported by CRO and distribution partnerships.

We are launching our Series A to accelerate platform automation and transfer, expand the Pleiad product and assay portfolio, grow our international partner network and advance our first human-relevant assay toward regulatory qualification.

IAMA Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative treatments for central nervous system disorders. The lead compound, IAMA-6, is a selective NKCC1 inhibitor designed to restore chloride homeostasis and rebalance GABAergic signaling. The mechanism has been studied in multiple CNS disorders, including Neurodevelopmental Disorders, such as Fragile X, Down Syndrome and Autism Spectrum disorders, and psychiatric and neurological conditions.

With a successfully completed phase 1 study, IAMA-6 is progressing to a Phase 2a proof of concept study in Fragile X which will be initiated late 2026.

IAMA is funded through phase 2 and is seeking funds to expand the clinical development program.

Ksilink is creating a NewCo to advance a first-in-class disease-modifying therapy for Parkinson’s disease. Built on a novel intracellular α-synuclein clearance mechanism, the program aims to address the underlying drivers of disease progression rather than symptoms alone.

The lead asset has demonstrated compelling activity in multiple patient-derived Parkinson’s disease models and encouraging early in vivo results, supported by a strong intellectual property position and a differentiated small-molecule approach.

The NewCo has been fully structured for a seamless transfer of patents, know-how, data, and development assets, providing a clear pathway toward clinical development and future partnering opportunities.

Ksilink is seeking investment partners to accelerate the program and build a leading neurodegeneration company around this innovative approach.

Neumirna Therapeutics is a biotechnology company developing RNA based therapies for neurological disorders dedicated to transforming patients’ lives.

Founded in 2020 in Copenhagen, Denmark by Dr. Henrik Klitgaard and Prof. Sakari Kauppinen, the company is advancing therapies for neurological diseases through the modulation of microRNAs.

Neumirna’s portfolio includes a clinical candidate, NMT.001, for drug resistant epilepsy, and a preclinical program in Parkinson’s disease. The company completed its Series A financing in January 2025 and is currently raising a Series B round.

Nucleome Therapeutics is decoding disease-associated genetic variants in the non-coding genome to discover first-in-class medicines. Nucleome’s technology combines pioneering 3D genome analysis with machine learning. We are mapping variants in regulation of gene expression to molecular pathways of inflammatory diseases with unprecedented precision and scale. Revealing mechanisms of disease from variation in gene regulation allows Nucleome to identify drug targets with much higher clinical success rates than previously possible. Nucleome is building a pipeline of antibody therapeutics to these targets. Lead program NTP464 is in preclinical development, with potential to resolve of inflammation across a wide range of inflammatory diseases.

O11 is a biotech spin-off from Aachen University Hospital developing an entirely novel COPD drug to tackle hypercapnia. Having demonstrated preclinical safety and efficacy and establshing GMP production, O11 is now ready for Phase 1 and is currently raising Series A.

Oncostellae is a clinical-stage biopharmaceutical company developing OST-122, a differentiated, gut-restricted small-molecule therapy for inflammatory bowel disease.

OST-122 is an oral JAK3/TYK2/ARK5 inhibitor designed to deliver potent anti-inflammatory activity directly within the gastrointestinal tract while minimizing systemic drug exposure. This pharmacological profile seeks to capture the rapid efficacy and convenience of oral JAK inhibition while reducing the systemic safety liabilities that can limit this otherwise highly effective therapeutic class.

In a randomized, double-blind, placebo-controlled Phase IIa proof-of-concept study in patients with moderate-to-severe ulcerative colitis, OST-122 demonstrated a favorable safety and pharmacokinetic profile together with encouraging clinical activity after only four weeks of treatment. High local drug concentrations in the gastrointestinal tract combined with minimal systemic exposure provide clinical validation of its intended gut-restricted profile.

OST-122 is now positioned for further clinical development in ulcerative colitis, with the potential to establish a new therapeutic approach to IBD: powerful oral immunomodulation where it is needed, while minimizing exposure where it is not.

OxSonics is a clinical-stage oncology company based in Oxford, UK, spun out of the University of Oxford's Institute of Biomedical Engineering. A first In Man clinical study was completed in 2025 with 26 patients enrolled and treated showing safety and early efficacy improvement of standard of care treatment for advanced mCRC patients (Cetuximab and Folfiri).

Our Mantra is simple: Make Precision Medicine in Oncology a true reality for more patients by harnessing the power of ultrasound-based drug delivery solutions. Every single cancer patient receives the right drug dose at the right time, at the right place to maximize treatment outcome.

Panosome GmbH is a Heidelberg, Germany-based, DKFZ-derived biotechnology company developing antibody therapeutics against disease targets that conventional discovery methods cannot reach. Founded by Prof. Nina Papavasiliou (CEO), Dr. Joey Verdi (CSO) and Dr. Erec Stebbins (COO), the company has built VAST (VSG-Immunogen Array by Sortase Tagging), a proprietary platform that uses the densely protein-coated surface of Trypanosoma brucei to display small, structurally complex epitopes at extremely high density, driving the immune system to generate high-affinity antibodies against targets that standard immunization approaches cannot access.

The platform has been validated in two settings: a peer-reviewed proof-of-concept antibody that neutralized fentanyl toxicity in mice, and Panosome's lead program, a first-in-class radioimmunoconjugate targeting a tumor-specific glycoform of MUC1. MUC1 is broadly expressed across solid tumors and ranked by the U.S. National Cancer Institute among the highest-priority antigen targets in oncology, yet disease-specific glycoforms have evaded prior antibody discovery efforts.

Panosome is preparing an EMA Scientific Advice meeting to align on a Phase 1 trial of its lead asset. Its platform and antibody assets are protected by five patent families, with a sixth in the drafting phase, for which the company has unihibited commercialization rights.

To date, Panosome has secured approximately €3.2M in non-dilutive German government grants, €2.4M in private and public investment, and a platform collaboration with a major U.S. pharmaceutical company (€800K upfront plus milestones), and is in active discussions with two additional global pharma partners. Panosome is seeking an investment in the range of 10M to bring its lead asset up to Phase I initiation.

Persica Pharmaceuticals is a clinical-stage biotechnology company developing PP353, a potentially disease-modifying, non-opioid treatment for vertebrogenic lumbar back pain (vLBP), a type of chronic low back pain (cLBP) associated with Modic type changes.

PharmNovo is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain, an area with significant unmet medical need. The company’s lead candidate, PN6047, is a potential first-in-class DORA (Delta Opioid Receptor Agonist) and represents a safer, non-addictive treatment for neuropathic pain.

Selonterra, Inc. (www.selonterra.com) develops proprietary, small molecule GPR4 agonists to reverse APOE4-induced neuronal dysfunction for the therapy of Alzheimer’s disease.

Selonterra’s GPR4 agonists offer a unique opportunity for early intervention in Alzheimer’s disease with compelling effects on well-established and novel biomarkers.

Selonterra is located in San Mateo, California, and funded by Nan Fung Life Sciences and the Schaller-Nikolich Foundation. In addition, we secured 5 MM in non-dilutive funding from the Michael J. Fox Foundation.

The key genetic determinant of AD is the APOE4 variant. Our breakthrough discovery is that APOE4 creates a new transcription factor binding site, which was independently confirmed by a leading academic group. This in turn leads to the downregulation of the G protein coupled receptor GPR4 in its vicinity on human chromosome 19.

Our patent protected, selective, non-neurotoxic small molecule GPR4 agonists reactivate the downregulated GPR4 pathway. This restores cognition-relevant long-term potentiation (LTP) deficits in hippocampi of two independent animal models of AD, an activity that is particularly hard to achieve.

Moreover, these lead compounds restore APOE4-caused dysfunction of gene expression and normalize biomarker profiles (Abeta, phospho Tau, BDNF) in iPSC-derived human neurons.

We seek funding or a partnership to develop these small molecules to a development compound with in vivo activity and optimal pharmacokinetics properties to then enter into IND-enabling studies and a Phase 1 clinical study.

SpliceBio is a clinical-stage, genetic medicines company harnessing its proprietary Protein Splicing platform to develop gene therapies for diseases that currently cannot be treated because the necessary gene is too large to be delivered by adeno-associated virus (AAV) vectors. The company’s lead program SB-007, aimed at addressing the root genetic cause of Stargardt disease by delivering the full-length ABCA4 protein, is being evaluated in the Phase 1/2 ASTRA study. SB-007 has completed the dose escalation portion of the study and is now being evaluated in 57 patients in a controlled and randomized Phase 2.

In addition to ophthalmology, SpliceBio has developed a franchise targeting monogenic CNS indications out of reach of conventional gene therapy. Our lead CNS program is aimed at an indication with over 30,000 patients and has generated compelling preclinical efficacy data in animal models, as well as robust expression in the Non-Human Primate brain, providing translational validation of the platform in the CNS.

SWISS Orphan EDC AG is a new, "Breakthrough Beyond IO Oncology Company" based in Switzerland and Houston / Dallas, Texas, USA. We aim to bring better, cutting edge "breakthrough" molecules and technologies faster and better to markets and patients than any other company worldwide. We believe this is possible and our ethical mission (EDCs, ethics driven companies).

The strategy is leading edge innovation to first tackle only the hardest to cure cancer types in MAIN and in RARE cancer indications

Today, at SWISS Orphan EDC AG, we leverage our very strong in vivo animal data in GBM (glioblastoma multiple, brain tumors) where only one chemo-therapy is approved, Temodal, today.

We have impressive data showing strong passage of blood brain barrier (BBB) and impressive efficacy in first models, too. Including high medical need (radiation, surgery, temozolomide) we will target this area (3-4/100.000) and combine it with a group of HCC, hepatological and bile liver cancer types, too. We work with leading OLs and KOLs also in regulatory (Swissmedic, FDA) in GBMs and other RARES, too.

We need 13.3 M CHF to be end-to-end financed in above RARE indications with Phase Ib. In our base-case, we show an EVA of X-factor 8.8 over 5 years with an IRR of 62%. Risks are calculated already and there is a salvage plan should all studies disappoint which we do not see at all. Post Phase Ib, we target "fast track" processes in the US and in Switzerland, and can partner, exit or can offer investors to carry their program forward, ideally with a major pharmaceutical player as a co-financing partner, too. We are always open and fair while focused and delivering. We are EDCs, ethics driven companies.

T-CURX is a German, venture-backed, clinical-stage biotech company headquartered in Würzburg, with additional labs and offices in Munich, Bavaria, with a wholly-owned subsidiary, Pantherna-Therapeutics, in Brandenburg and Berlin (www.pantherna-therapeutics.com). T-CURX has the ambition to democratize CAR-T cell therapies by leveraging its proprietary non-viral CAR-T cell technologies for developing in vivo CAR-T therapies, in order to make CAR-T therapies more accessible and affordable to cancer patients.

T-CURX CAR-T technology is based on T cell-targeted LNP delivery of either Sleeping Beauty transposon mRNA mcDNA vectors allowing stable CAR expression for cancer indications, or delivery of optimized mRNA-based CAR vectors for autoimmune indications. T-CURX is also pursuing clinical development of autologous, ex vivo CAR-T programs against a novel target, Siglec-6, in AML and CLL, and two additional CAR-T programs against non-disclosed targets, addressing novel targets relevant for both hematological malignancies, as well as solid tumor indications.

Valink Therapeutics discovers and develops complex biologics with standard-of-care potential. Our LiliumX platform unlocks high throughput, unbiased screening of multi-specific antibodies with or without payload (ADCs, AOCs, and DACs) and functionalities such as immune cell engagement and receptor agonism. A pre-clinical biotechnology company, Valink’s two lead assets are bsADCs for solid tumours with excellent in vivo POC, as part of a rich pipeline of internal assets across indications and modalities.

We are open to investment conversations, out-licensing discussions around assets in our pipeline, as well as discovery partnerships focused on oncology, immunology, and other indications well suited to biologics.

Valink Therapeutics is headquartered in Cambridge, Massachusetts with a research and development facility in the United Kingdom.

Following the first Phase 3 validation of personalized neoantigen immunotherapy, YGION Biomedical is advancing YG-01, a Phase 1-ready personalized neoantigen immunotherapy designed to prevent cancer recurrence, developed from concept to clinic in just four years.

Adularia is a preclinical-stage biotech spin-off from the University of Zurich, developing novel small-molecule cancer immunotherapies.

Through deep research into the symbiotic interplay between gut microbes and the immune system, we identified a novel therapeutic target for immuno-oncology that is predominantly expressed on tumor-residing myeloid cells. Once stimulated, these macrophages release cytokines that activate cytotoxic T-cells, leading to enhanced tumor infiltration and a potent anti-tumor effect.

Leveraging this discovery, we developed our lead candidate, a small molecule that reprograms immunosuppressive myeloid cells within the tumor microenvironment into an immunostimulatory, tumor-fighting state. This targeted, well-tolerated approach has the potential to bring immunotherapy to patients with "cold" tumors that today's treatments leave behind.

CARTemis Therapeutics is a science-driven clinical-stage spin-off from the Max Delbrück Center in Berlin, founded in 2023 to translate breakthrough immunotherapy research into durable clinical solutions.

We are redefining CAR T therapy, which today delivers effective treatment in only about half of patients. Our platform tackles two of the most significant limitations of current CAR-T therapies. Suboptimal patient response rates and limited scalability are addressed through our first-in-class CXCR5-targeting approach combined with a proprietary hybrid in vivo delivery strategy.

Our proprietary CXCR5-targeting technology uniquely addresses both malignant cells and the tumor-supportive microenvironment, while our hybrid in vivo delivery approach is designed to expand patient access without compromising safety.

To date, we have secured nearly €5 million in non-dilutive funding, enabling substantial de-risking of our CXCR5 program through an upcoming investigator-initiated Phase I/IIa trial (TICARA) currently being prepared at Charité Berlin for patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Given the role of CXCR5 in the formation of disease-causing autoantibodies, CXCR5 targeting will be relevant beyond oncology for the treatment of B-cell-mediated autoimmune diseases.

We are now raising seed financing round to advance our hybrid in vivo anti-CXCR5 CAR T program to IND readiness.

CD4 Therapeutics is a Munich-based biotechnology company focused on autoimmune diseases, founded by an experienced team of scientists, physicians and entrepreneurs.

The company has secured a €12 million investment commitment from the lead investor, a German family office affiliated with a midsize pharmaceutical company, towards an €20 million Seed financing. CD4 Therapeutics is seeking an additional €8 million from fellow family offices to complete the syndicate. A further €6 million in non-dilutive funding from the German federal government has been committed alongside the round. The lead investor previously participated in the €2 million Friends & Family round, completed in April 2026.

The company’s lead asset, Tregalizumab, is the only clinical-stage anti-CD4 monoclonal antibody with a validated first-in-class mechanism of action: selective activation of regulatory T cells (Tregs) to restore immune tolerance. This approach was recognized by the 2025 Nobel Prize in Medicine.Across approximately 700 patients with rheumatoid arthritis and psoriasis, Tregalizumab demonstrated clinical efficacy and the expected immune modulation, together with a remarkably clean safety profile. In a Phase IIb rheumatoid arthritis study, post-hoc analyses showed efficacy comparable to Humira when optimally dosed, with an ACR70 response rate of 25% at week 48 versus approximately 5% for methotrexate alone (n=321).

The Seed financing will fund the production of Tregalizumab and the first clinical trial, while enabling the company to advance its broader clinical development strategy. Over the next three years, CD4 Therapeutics plans to initiate Phase IIb proof-of-concept trials in oral lichen planus and/or vulvar lichen sclerosus and acute graft-versus-host disease, as well as a pilot Phase IIa or investigator-initiated trial in biologics-refractory rheumatoid arthritis.

Tregalizumab addresses autoimmune markets exceeding €20 billion. A broad patent portfolio, biomarker-based IP, and regulatory protections, including FDA Orphan Drug Designation for acute GvHD, are expected to provide exclusivity until approximately 2045.

Cereus Biosciences is pioneering the next generation of therapeutic cancer vaccines—designed to be universal, off-the-shelf, and scalable. Founded at Institut Curie, Cereus combines computational genomics, multi-omics and immunology to unlock a critical opportunity in precision oncology: shared tumor-specific neoantigens that can be targeted across patient populations.

Cereus’ proprietary discovery approach explores previously underexamined regions of the genome, including the “dark genome,” to identify novel cancer-specific antigens with potential for broad therapeutic application. This enables a fundamentally different model from personalized cancer vaccines, with the potential to reduce manufacturing complexity, shorten development timelines, and expand patient access.

The company is initially advancing its strategy in pancreatic cancer, while its platform has demonstrated applicability across multiple cancer types.
With deep scientific roots, proprietary discovery capabilities and a scalable product vision, Cereus is positioned to build a new therapeutic vaccine platform for oncology—addressing major unmet medical needs while targeting a potentially significant and underpenetrated market.

As clinical-stage pharmaceutical, CheckBrain Therapeutics develops novel break-through therapies for diseases of the human brain. We have the clear potential of a first-time neuroprotective blockbuster medication in acute stroke to halt progression of acute neurotoxic damage.

The unmet need in acute stroke for annually over 3.4 million cases is not limited to acute mortality reduction, but extends to prevention of long-term disability, dependency, and societal burden. Today, only dissolving the occlusion works for only in 10 per cent of patients with limited time windows of 4.5–6 h from onset. All other patients have no therapy available, putting a significant long-term burden on patients, families, caregivers, payors, and societies.

CheckBrain Therapeutics targets post-stroke hyperexcitation with lead small-molecule currently completing a first-in-human Phase 1/2a trial. By combining broad acute ischemic stroke treatment with a de-risked stratification approach in genetically defined high-responders, a pivotal Phase 2 trial can be initiated in 2027.

Gibela is a Basel-based company exploring a novel and proprietary target to treat certain cholestatic liver diseases and metabolic disease with siRNA therapeutics.

Gibela owns IP allowing us uniquely to target CNNM4, for which we have two siRNA lead molecules at pre-IND stage. Gibela’s clinical candidates are intended to treat Primary Biliary Cholangitis (PBC), a rare liver disease, and MASH.

Hepatic CNNM4 is a magnesium transporter over-expressed in these diseases, leading to endoplasmic reticulum stress and mitochondrial dysfunction. Silencing CNNM4 in vivo has proven efficacious in no less than 5 liver diseases as published in peer-reviewed journals.

Gibela is now actively raising Series A to progress the two target indications.

kezbio designs next-generation small molecules to unlock the therapeutic potential of clinically validated and emerging targets at the intersection of metabolism, fibrosis and oncology, many of which have long been considered beyond the reach of traditional drug discovery.

kezbio develops new tissue-specific covalent inhibitors for liver fibrosis (MASH) and hepatocellular carcinoma (HCC).

Our proprietary Intelligent Fragment Evolution Platform, powered by our Selectase® enzyme family, gives us access to new chemical space that is synthesizable by design, delivering target-validated results within weeks. We engineer precision covalent drugs that selectively modulate disease-driving proteins, built for improved selectivity, efficacy, and durable target engagement.

Founded in 2022 and based in the Potsdam, Germany, kezbio has raised over €3.4M in dilutive and non-dilutive funding to date, including support from the State of Brandenburg, Germany, and the EU.

Maeve Therapeutics is a Netherlands-based biotech developing non-hormonal, disease-modifying therapies for endometriosis and other women's health conditions of high unmet need. Our lead programme simultaneously targets pain, inflammation and fibrosis in endometriosis.

Meddenovo Drug Design is a Lyon-based drug design company developing cyclic peptide therapeutics for oncology and radiopharmaceuticals. The company was founded to address a fundamental bottleneck in early drug discovery: the difficulty of generating viable lead candidates for complex and hard-to-drug targets when no starting molecule exists.

Meddenovo is incubated at Bayer Life Hub, benefiting from a strong innovation ecosystem and close interaction with industry expertise. The company has raised €1.7M in total funding, combining equity and non-dilutive support. Meddenovo is also an i-Lab laureate, a highly selective French government deep-tech program that recognizes startups with high innovation potential, and significant growth prospects. Through this program, Meddenovo receives direct public funding and benefits from long-term institutional trust, reflecting national-level confidence in its technology and team.

After finalizing its pre-seed round in 2025, Meddenovo successfully achieved its planned development and business milestones. In less than two years, the company advanced its technology into a robust, ready-to-use AI platform dedicated to cyclic peptide drug design, which is now actively applied in drug discovery projects.

Meddenovo’s proprietary AI/ML-powered platform enables the de novo design and optimization of cyclic peptide drug candidates. Unlike traditional approaches that depend on prior experimental data or limited libraries, the platform allows rational exploration of a large and biologically relevant chemical space while prioritizing drug-like properties, target engagement, and functionalization potential. This makes the technology particularly well suited for oncology applications, including targeted radiopharmaceuticals.

Meddenovo advances its own internal pipeline while forming strategic partnerships with pharmaceutical companies. The company has already entered into a partnership agreement with a large pharmaceutical group, providing early industrial validation of its scientific approach and technology.

Meddenovo is currently preparing its seed financing round, planned to be finalized in 2026, to further advance its cyclic peptide pipeline and expand strategic partnerships in oncology.

Metaimmune develops small molecules that treat inflammatory, autoimmune and neurodegenerative diseases by metabolically reprogramming immune cells. By targeting the metabolic state of immune cells, we harness the body’s own feedback mechanisms to actively resolve inflammation. What makes us unique:

• Novel mechanisms: We have mapped the immunometabolic switches that return inflamed immune cells to homeostasis.
• Active resolution, not blockade: Our compounds push activated immune cells into a pro-resolving state rather than simply suppressing them.
• Broad, endogenous biology: These natural resolution programs act across multiple pathways and diseases.

Our pipeline comprises two potential first-in-class programs in areas of high unmet medical need and strong pharma interest:

1. A broad yet selective type I interferon blocker, inspired by a novel anti-inflammatory metabolite and building on unpublished findings from co-founder Andrea Ablasser.
2. Metabolic reprogramming compounds designed to match the efficacy of glucocorticoids with fewer side effects, based on pioneering science (Nature 2024) from co-founders Eicke Latz and Gerhard Krönke.

Our scientific founders – Eicke Latz, Andrea Ablasser and Gerhard Krönke – are leading experts in immunometabolism and innate immunity, with deep translational experience and unique access to patient samples that inform our development programs.

Our management team is the former core team of IFM Therapeutics, which delivered three major exits in just eight years – and we are applying the same playbook at Metaimmune.

We are raising a EUR 10 million seed round to advance one program into lead optimization and the other to development candidate selection within 18 months.

MONCYTE Health is a health technology company developing a novel solution that integrates cellular diagnostics with robotics, high-resolution imaging, advanced software, and artificial intelligence (AI). The focus of the solution is to uncover and analyze the cellular mechanisms driving inflammation within atherosclerotic plaque, a key factor in cardiovascular disease.

This multidisciplinary approach provides deep biological data unveiling real-time immune cell function and enabling clinically actionable, direct insight into current health status. This unique data allows healthcare professionals to better detect residual cardiovascular risk earlier, personalize treatment decisions, and monitor disease progression more effectively. The technology is designed to generate new, clinically relevant data also for pharmaceutical companies developing next-generation cardiovascular and inflammation-modulating therapies.

Nanolynx Biologics is a Swiss biotech and spinout of Ability Biotherapeutics developing Conditionally Active Nanobody-Drug Conjugates (CA-NDCs) for solid tumors.

Conventional antibody-drug conjugates are limited by poor tumor penetration and toxicity from binding to healthy tissue. Nanolynx Biologics addresses both challenges by combining small nanobody-based binders with an AI-engineered pH switch designed to activate binding in the acidic tumor environment while reducing binding in healthy tissue.

Our proprietary IntelliBody™ platform is powered by one of the world’s largest nanobody datasets and is designed to generate conditionally active binders across targets. The platform is modular and applicable across drug conjugates and oncology.

The team has demonstrated the conditional-activation principle on a different molecule and target at Ability Biotherapeutics. Our first program targets Tissue Factor, a clinically validated oncology target, initially in pancreatic and head & neck cancers.

Nanolynx Biologics is seeking pharma partners for early platform licensing and investors for its CHF 7M Seed round, with a CHF 1.1M angel tranche currently open, to advance its lead CA-NDC and validate the IntelliBody™ platform.

Nerai develops in vivo CRISPR editors that reach mutations others cannot. A single editor treats many rare diseases, compounding small, individually unprofitable orphan indications into one scalable, blockbuster-scale asset. Our vision: no disease stays too rare to be worth a cure.

NeutroGen Therapeutics is developing CryoEndure, an allogeneic, cryopreservable neutrophil transfusion designed for patients whose immune cells have been depleted by intensive cancer treatment.

Our first focus is severe neutropenia in acute myeloid leukaemia (AML), particularly when infections persist despite standard treatment.

CryoEndure is produced from donor stem cells and can be manufactured and stored ahead of use, with the aim of making neutrophil transfusions available when patients need them. We have demonstrated post-thaw viability and antimicrobial activity in preclinical studies. Current work focuses on scaling production, validating manufacturing costs and testing efficacy in vivo.

Nœtica Pharma, a biotech founded in September 2025 by the French startup studio Technofounders, develops a new class of patented small molecules with neuroprotective, antioxidant, and neuroregenerative properties.

Its lead drug candidate, BRT002, targets Neonatal Hypoxic-Ischemic Encephalopathy (NHIE), an orphan pediatric condition (EMA ODD granted) with devastating consequences (death, disability) affecting 1 to 2 million children per year worldwide, with no treatment available to date.

BRT002 is the result of 10 years of research (CEA, Women and Infant Hospital of New England) that led to the filing of two patents (molecules – 2021, granted; and biomarkers – 2024). It has repeatedly demonstrated, in a representative NHIE model, its ability to protect and restore brain tissue, significantly reducing neurological sequelae, with a favorable safety profile.

Nœtica Pharma has been funded with 700k€ at the pre-seed stage by Technofounders, BPIFrance FTS and a Business Angel. Winner of the i-Lab 2026 award, it is led by a highly qualified team from the biotech industry.

BRT002 is now ready to begin regulatory preclinical development under a program validated by the ANSM following a scientific advice meeting, before starting a Phase 1a-b clinical trial including NHIE patients.

Nœtica Pharma is currently raising fund to pursue the development of BRT002 and to perform additional proof-of-concept preclinical studies to expand its pipeline to broader indications.

PureDEL is an ETH spin-off developing oral and cell permeable synthetic macrocycles for challenging disease targets. PureDEL's proprietary platform unlocks physical screening of billions of synthetic macrocycles in a single experiment.

Synameta Therapeutics is a highly innovative Swiss biotech company developing next-generation exosome-based vectors for targeted therapies.

⚙️ Built on a novel nanomedicine platform, Synameta enables breakthrough medicines to achieve the outcomes they were designed for. They're working on unlocking the full potential of innovative drug candidates by enhancing intracellular delivery, reducing risk in clinical development and amplifying therapeutic impact.

🧬 With applications spanning cancer treatment to gene therapy, the company is working to establish its biovectors as a universal standard for targeted therapeutic delivery, transforming today’s innovations into tomorrow’s cures.

Swiss seed-stage radiopharma company. Lead program: FAP theranostic pair THKS-3698 (18F PET) and THKS-2698 (177Lu RLT); IND-ready, first clinical imaging data, Phase I planned for 2027. Differentiated small-molecule FAP platform with strategic isotope, CDMO, and clinical access.

CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders.

Until August 2023, CervoMed was known as EIP Pharma Inc. EIP Pharma Inc is now a wholly-owned subsidiary of CervoMed.

We believe the neurodegenerative process, in the early stages, is primarily comprised of neuroinflammation-induced damage to synapses, which are the interconnections between nerve cells, or neurons. Our lead product candidate, neflamapimod, is currently in clinical development as a treatment for neurodegenerative diseases, such as dementia with Lewy bodies, frontotemporal dementia and recovery after stroke.

We have assembled a highly experienced leadership team to develop and commercialize innovative drug treatments for dementia with Lewy bodies and other central nervous system disorders.